Bruce Bender
Concepts (384)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 85 | 2023 | 2042 | 11.270 |
Why?
| Patient Compliance | 25 | 2020 | 526 | 4.810 |
Why?
| Anti-Asthmatic Agents | 20 | 2022 | 350 | 4.460 |
Why?
| Medication Adherence | 24 | 2022 | 537 | 4.330 |
Why?
| Adrenal Cortex Hormones | 21 | 2022 | 499 | 2.320 |
Why?
| Pulmonary Disease, Chronic Obstructive | 10 | 2023 | 928 | 2.080 |
Why?
| Telemedicine | 8 | 2022 | 665 | 1.880 |
Why?
| Bronchodilator Agents | 8 | 2020 | 243 | 1.710 |
Why?
| Food Hypersensitivity | 4 | 2020 | 254 | 1.620 |
Why?
| Dermatitis, Atopic | 8 | 2018 | 307 | 1.580 |
Why?
| Electronic Mail | 2 | 2021 | 54 | 1.420 |
Why?
| Health Personnel | 4 | 2021 | 574 | 1.290 |
Why?
| Adrenergic beta-Agonists | 3 | 2020 | 126 | 1.270 |
Why?
| Patient Education as Topic | 9 | 2021 | 678 | 1.230 |
Why?
| Health Communication | 2 | 2018 | 41 | 1.170 |
Why?
| Self Care | 7 | 2021 | 350 | 1.160 |
Why?
| Humans | 123 | 2023 | 114935 | 1.140 |
Why?
| Speech Recognition Software | 2 | 2018 | 11 | 1.120 |
Why?
| Rhinitis, Allergic | 2 | 2018 | 35 | 1.070 |
Why?
| Child | 50 | 2023 | 18366 | 0.950 |
Why?
| Stress, Psychological | 5 | 2018 | 945 | 0.940 |
Why?
| Administration, Inhalation | 18 | 2023 | 642 | 0.930 |
Why?
| Disease Management | 3 | 2018 | 563 | 0.930 |
Why?
| Glucocorticoids | 4 | 2016 | 534 | 0.880 |
Why?
| Bullying | 2 | 2016 | 23 | 0.880 |
Why?
| Metered Dose Inhalers | 5 | 2012 | 14 | 0.870 |
Why?
| Anti-Allergic Agents | 3 | 2018 | 41 | 0.870 |
Why?
| Parents | 12 | 2022 | 1191 | 0.850 |
Why?
| Reminder Systems | 3 | 2015 | 162 | 0.830 |
Why?
| Communication | 3 | 2021 | 749 | 0.820 |
Why?
| Cell Phone | 2 | 2021 | 77 | 0.800 |
Why?
| Sleep Wake Disorders | 7 | 2016 | 232 | 0.760 |
Why?
| Personnel Management | 1 | 2021 | 11 | 0.750 |
Why?
| Text Messaging | 2 | 2020 | 154 | 0.740 |
Why?
| Telecommunications | 2 | 2018 | 16 | 0.730 |
Why?
| Tobacco Products | 1 | 2022 | 101 | 0.730 |
Why?
| Rhinitis, Allergic, Seasonal | 3 | 2005 | 32 | 0.730 |
Why?
| Monitoring, Physiologic | 3 | 2019 | 248 | 0.720 |
Why?
| Delivery of Health Care | 5 | 2023 | 834 | 0.720 |
Why?
| Research Design | 4 | 2023 | 932 | 0.710 |
Why?
| Self-Management | 2 | 2019 | 126 | 0.700 |
Why?
| Electronic Health Records | 2 | 2018 | 802 | 0.690 |
Why?
| Nurse-Patient Relations | 1 | 2020 | 43 | 0.680 |
Why?
| Quality of Life | 12 | 2020 | 2359 | 0.670 |
Why?
| Biological Products | 1 | 2022 | 169 | 0.670 |
Why?
| Minority Groups | 5 | 2017 | 228 | 0.670 |
Why?
| Treatment Adherence and Compliance | 1 | 2019 | 18 | 0.660 |
Why?
| Hypersensitivity | 3 | 2022 | 256 | 0.650 |
Why?
| Workload | 1 | 2020 | 132 | 0.640 |
Why?
| Organizational Culture | 1 | 2020 | 119 | 0.640 |
Why?
| Adrenergic beta-2 Receptor Agonists | 2 | 2019 | 32 | 0.630 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2015 | 93 | 0.630 |
Why?
| Prescription Drug Overuse | 1 | 2018 | 11 | 0.620 |
Why?
| Health Behavior | 3 | 2013 | 704 | 0.610 |
Why?
| Substance-Related Disorders | 2 | 2022 | 946 | 0.610 |
Why?
| Motivation | 2 | 2020 | 495 | 0.600 |
Why?
| Behavioral Medicine | 1 | 2018 | 37 | 0.600 |
Why?
| Health Promotion | 2 | 2014 | 686 | 0.590 |
Why?
| Urticaria | 1 | 2018 | 50 | 0.590 |
Why?
| Androstadienes | 3 | 2008 | 97 | 0.560 |
Why?
| Spirometry | 5 | 2021 | 225 | 0.560 |
Why?
| Male | 53 | 2022 | 55663 | 0.550 |
Why?
| Fluticasone-Salmeterol Drug Combination | 1 | 2016 | 12 | 0.550 |
Why?
| Laryngeal Diseases | 1 | 2016 | 21 | 0.550 |
Why?
| Tobacco Smoke Pollution | 2 | 2014 | 217 | 0.550 |
Why?
| Physician-Patient Relations | 4 | 2014 | 463 | 0.550 |
Why?
| Adaptation, Psychological | 2 | 2018 | 547 | 0.530 |
Why?
| Female | 55 | 2022 | 59580 | 0.530 |
Why?
| Surveys and Questionnaires | 15 | 2021 | 4635 | 0.520 |
Why?
| Science | 1 | 2016 | 48 | 0.520 |
Why?
| Laryngoscopy | 1 | 2016 | 93 | 0.510 |
Why?
| Adolescent | 29 | 2022 | 17829 | 0.510 |
Why?
| Primary Health Care | 5 | 2021 | 1515 | 0.510 |
Why?
| Anxiety | 5 | 2016 | 846 | 0.510 |
Why?
| Behavior Therapy | 1 | 2018 | 226 | 0.510 |
Why?
| Desensitization, Immunologic | 2 | 2018 | 117 | 0.500 |
Why?
| Research Report | 1 | 2015 | 75 | 0.500 |
Why?
| Telephone | 3 | 2020 | 152 | 0.480 |
Why?
| Pulmonary Medicine | 2 | 2016 | 87 | 0.480 |
Why?
| Airway Obstruction | 1 | 2016 | 168 | 0.470 |
Why?
| Clinical Trials as Topic | 2 | 2012 | 934 | 0.470 |
Why?
| Sublingual Immunotherapy | 1 | 2014 | 7 | 0.460 |
Why?
| Adult | 26 | 2023 | 30608 | 0.460 |
Why?
| Diagnostic Techniques and Procedures | 1 | 2014 | 13 | 0.460 |
Why?
| Therapeutics | 1 | 2014 | 12 | 0.460 |
Why?
| Pruritus | 4 | 2010 | 60 | 0.450 |
Why?
| Quality of Health Care | 1 | 2018 | 573 | 0.450 |
Why?
| Community-Institutional Relations | 1 | 2014 | 89 | 0.450 |
Why?
| Motivational Interviewing | 1 | 2014 | 87 | 0.420 |
Why?
| Depression | 6 | 2018 | 1134 | 0.420 |
Why?
| Oxygen Inhalation Therapy | 1 | 2014 | 129 | 0.410 |
Why?
| Family | 4 | 2022 | 590 | 0.410 |
Why?
| Nebulizers and Vaporizers | 5 | 2023 | 78 | 0.400 |
Why?
| United States | 13 | 2021 | 12211 | 0.390 |
Why?
| Organizational Affiliation | 1 | 2011 | 8 | 0.380 |
Why?
| Behavioral Research | 1 | 2011 | 34 | 0.380 |
Why?
| Severity of Illness Index | 10 | 2019 | 2542 | 0.370 |
Why?
| Socioeconomic Factors | 6 | 2022 | 1081 | 0.370 |
Why?
| Psychomotor Performance | 2 | 2004 | 280 | 0.370 |
Why?
| Physical Therapy Modalities | 1 | 2014 | 264 | 0.370 |
Why?
| Budesonide | 5 | 2012 | 87 | 0.370 |
Why?
| Reinforcement, Verbal | 1 | 2010 | 2 | 0.350 |
Why?
| Art Therapy | 1 | 2010 | 15 | 0.350 |
Why?
| Patient Participation | 2 | 2018 | 360 | 0.340 |
Why?
| Health Services Accessibility | 2 | 2015 | 765 | 0.340 |
Why?
| Middle Aged | 21 | 2020 | 26806 | 0.340 |
Why?
| Critical Care | 3 | 2021 | 474 | 0.330 |
Why?
| Intensive Care Units | 1 | 2014 | 619 | 0.330 |
Why?
| Chronic Disease | 6 | 2018 | 1593 | 0.330 |
Why?
| Curriculum | 1 | 2015 | 845 | 0.330 |
Why?
| Focus Groups | 3 | 2011 | 385 | 0.320 |
Why?
| Child, Preschool | 13 | 2021 | 9086 | 0.320 |
Why?
| Pain | 1 | 2014 | 710 | 0.300 |
Why?
| Retrospective Studies | 7 | 2023 | 12544 | 0.300 |
Why?
| Evidence-Based Medicine | 3 | 2021 | 675 | 0.300 |
Why?
| Young Adult | 9 | 2022 | 10478 | 0.300 |
Why?
| Fluticasone | 4 | 2018 | 87 | 0.290 |
Why?
| Cognition Disorders | 4 | 2014 | 476 | 0.290 |
Why?
| Technology | 2 | 2018 | 79 | 0.290 |
Why?
| Sleep | 3 | 2008 | 632 | 0.290 |
Why?
| Clinical Decision-Making | 2 | 2021 | 269 | 0.280 |
Why?
| Histamine H1 Antagonists | 2 | 2005 | 33 | 0.280 |
Why?
| Environmental Exposure | 2 | 2018 | 377 | 0.280 |
Why?
| Qualitative Research | 2 | 2020 | 936 | 0.280 |
Why?
| Health Literacy | 3 | 2021 | 164 | 0.280 |
Why?
| Prednisone | 5 | 2022 | 231 | 0.270 |
Why?
| Exercise | 1 | 2016 | 1643 | 0.270 |
Why?
| Albuterol | 1 | 2006 | 103 | 0.260 |
Why?
| Rhinitis, Allergic, Perennial | 1 | 2005 | 23 | 0.260 |
Why?
| Guideline Adherence | 2 | 2021 | 490 | 0.250 |
Why?
| Sex Chromosome Aberrations | 2 | 2002 | 51 | 0.250 |
Why?
| Mood Disorders | 1 | 2006 | 112 | 0.240 |
Why?
| Health Expenditures | 2 | 2016 | 171 | 0.240 |
Why?
| Health Knowledge, Attitudes, Practice | 5 | 2016 | 1183 | 0.240 |
Why?
| Data Collection | 1 | 2007 | 623 | 0.240 |
Why?
| Colorado | 6 | 2020 | 4091 | 0.240 |
Why?
| Social Class | 2 | 2022 | 204 | 0.240 |
Why?
| Caregivers | 2 | 2016 | 714 | 0.230 |
Why?
| Loratadine | 1 | 2004 | 3 | 0.230 |
Why?
| Hospitalization | 6 | 2020 | 1754 | 0.230 |
Why?
| Sleep Stages | 1 | 2004 | 61 | 0.230 |
Why?
| Health Resources | 2 | 2016 | 122 | 0.230 |
Why?
| Biomedical Research | 2 | 2021 | 585 | 0.230 |
Why?
| Salmeterol Xinafoate | 2 | 2018 | 41 | 0.220 |
Why?
| Overweight | 1 | 2007 | 472 | 0.220 |
Why?
| Research | 3 | 2016 | 395 | 0.220 |
Why?
| Nitric Oxide | 2 | 2019 | 827 | 0.220 |
Why?
| Histamine H1 Antagonists, Non-Sedating | 1 | 2003 | 1 | 0.220 |
Why?
| Diphenhydramine | 1 | 2003 | 30 | 0.210 |
Why?
| Patient Dropouts | 1 | 2003 | 66 | 0.210 |
Why?
| Risk-Taking | 1 | 2006 | 333 | 0.210 |
Why?
| Social Support | 4 | 2013 | 528 | 0.210 |
Why?
| Animals, Domestic | 1 | 2002 | 11 | 0.210 |
Why?
| Emotions | 2 | 2018 | 472 | 0.200 |
Why?
| Hypnotics and Sedatives | 1 | 2003 | 134 | 0.200 |
Why?
| Age Factors | 5 | 2016 | 2891 | 0.200 |
Why?
| Income | 1 | 2022 | 167 | 0.190 |
Why?
| Cost-Benefit Analysis | 2 | 2015 | 546 | 0.190 |
Why?
| Tobacco Use | 1 | 2022 | 60 | 0.190 |
Why?
| Health Services Needs and Demand | 1 | 2023 | 244 | 0.190 |
Why?
| Thoracic Diseases | 1 | 2021 | 13 | 0.190 |
Why?
| Adolescent Behavior | 1 | 2006 | 488 | 0.180 |
Why?
| Nedocromil | 3 | 2009 | 32 | 0.180 |
Why?
| Observational Studies as Topic | 1 | 2021 | 90 | 0.180 |
Why?
| Smartphone | 2 | 2018 | 70 | 0.180 |
Why?
| Quality Improvement | 2 | 2019 | 954 | 0.170 |
Why?
| Prospective Studies | 7 | 2022 | 6218 | 0.170 |
Why?
| Risk Factors | 8 | 2014 | 8637 | 0.170 |
Why?
| Models, Econometric | 1 | 2019 | 34 | 0.170 |
Why?
| Behavior Control | 1 | 2019 | 14 | 0.170 |
Why?
| Intelligence | 4 | 2007 | 131 | 0.160 |
Why?
| Patient-Centered Care | 2 | 2016 | 473 | 0.160 |
Why?
| Telemetry | 1 | 2018 | 36 | 0.160 |
Why?
| Receptor, ErbB-4 | 1 | 2018 | 18 | 0.160 |
Why?
| Allergists | 1 | 2018 | 19 | 0.160 |
Why?
| Drug Monitoring | 1 | 2019 | 184 | 0.150 |
Why?
| Exhalation | 1 | 2018 | 35 | 0.150 |
Why?
| Citalopram | 1 | 2018 | 27 | 0.150 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2016 | 1215 | 0.150 |
Why?
| Cloud Computing | 1 | 2017 | 7 | 0.150 |
Why?
| Antidepressive Agents, Second-Generation | 1 | 2018 | 38 | 0.150 |
Why?
| Confidentiality | 1 | 2018 | 67 | 0.150 |
Why?
| Patient Advocacy | 2 | 2020 | 66 | 0.150 |
Why?
| Respiratory System | 1 | 2019 | 138 | 0.150 |
Why?
| Health Plan Implementation | 1 | 2019 | 132 | 0.150 |
Why?
| Aged | 8 | 2019 | 19122 | 0.150 |
Why?
| Medical Informatics | 1 | 2018 | 92 | 0.140 |
Why?
| Respiratory Tract Diseases | 1 | 2018 | 140 | 0.140 |
Why?
| Health Surveys | 2 | 2009 | 443 | 0.140 |
Why?
| Biosensing Techniques | 1 | 2018 | 99 | 0.140 |
Why?
| Dry Powder Inhalers | 1 | 2016 | 2 | 0.140 |
Why?
| Sleep Medicine Specialty | 1 | 2016 | 9 | 0.140 |
Why?
| Suicidal Ideation | 2 | 2012 | 397 | 0.140 |
Why?
| Adrenergic beta-Antagonists | 1 | 2018 | 288 | 0.140 |
Why?
| Larynx | 1 | 2016 | 47 | 0.130 |
Why?
| Time Factors | 2 | 2021 | 6125 | 0.130 |
Why?
| Practice Guidelines as Topic | 4 | 2021 | 1400 | 0.130 |
Why?
| Air Pollution | 1 | 2018 | 170 | 0.130 |
Why?
| Respiration | 1 | 2016 | 180 | 0.130 |
Why?
| Mental Disorders | 2 | 2014 | 891 | 0.130 |
Why?
| Health Education | 1 | 2018 | 322 | 0.130 |
Why?
| Pilot Projects | 3 | 2013 | 1372 | 0.130 |
Why?
| Health Services | 1 | 2016 | 103 | 0.130 |
Why?
| Treatment Outcome | 8 | 2018 | 9105 | 0.130 |
Why?
| Problem Behavior | 1 | 2016 | 86 | 0.120 |
Why?
| Intention to Treat Analysis | 1 | 2015 | 68 | 0.120 |
Why?
| Anti-Inflammatory Agents | 3 | 2010 | 451 | 0.120 |
Why?
| Self Efficacy | 1 | 2018 | 355 | 0.120 |
Why?
| Depressive Disorder, Major | 1 | 2018 | 300 | 0.120 |
Why?
| Physicians | 1 | 2022 | 772 | 0.120 |
Why?
| Patient Reported Outcome Measures | 1 | 2016 | 250 | 0.120 |
Why?
| Patient Acceptance of Health Care | 3 | 2015 | 679 | 0.120 |
Why?
| Psychology | 1 | 2014 | 81 | 0.110 |
Why?
| Monosomy | 2 | 2004 | 10 | 0.110 |
Why?
| Follow-Up Studies | 4 | 2014 | 4427 | 0.110 |
Why?
| Pandemics | 1 | 2022 | 1325 | 0.110 |
Why?
| Sex Factors | 3 | 2009 | 1721 | 0.110 |
Why?
| Chromosomes, Human, X | 2 | 2004 | 60 | 0.110 |
Why?
| Aged, 80 and over | 3 | 2016 | 6364 | 0.110 |
Why?
| Referral and Consultation | 1 | 2018 | 634 | 0.110 |
Why?
| Community Health Services | 1 | 2015 | 212 | 0.110 |
Why?
| Cost Savings | 1 | 2013 | 74 | 0.110 |
Why?
| Administration, Oral | 3 | 2018 | 731 | 0.110 |
Why?
| Turner Syndrome | 2 | 2004 | 45 | 0.110 |
Why?
| Indians, North American | 1 | 2018 | 570 | 0.100 |
Why?
| Self Report | 2 | 2019 | 696 | 0.100 |
Why?
| Lung Diseases | 2 | 2016 | 703 | 0.100 |
Why?
| Emergency Service, Hospital | 2 | 2021 | 1813 | 0.100 |
Why?
| Ethanolamines | 1 | 2012 | 19 | 0.100 |
Why?
| Primary Prevention | 1 | 2013 | 171 | 0.100 |
Why?
| Program Evaluation | 2 | 2019 | 824 | 0.100 |
Why?
| Multimedia | 1 | 2011 | 10 | 0.100 |
Why?
| Thinking | 1 | 2012 | 54 | 0.100 |
Why?
| Equipment Design | 3 | 2020 | 511 | 0.100 |
Why?
| Needs Assessment | 1 | 2013 | 315 | 0.100 |
Why?
| Immunotherapy | 1 | 2015 | 475 | 0.090 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2018 | 1893 | 0.090 |
Why?
| Longitudinal Studies | 3 | 2007 | 2382 | 0.090 |
Why?
| Sickness Impact Profile | 1 | 2010 | 50 | 0.090 |
Why?
| Drug Therapy, Combination | 3 | 2012 | 954 | 0.090 |
Why?
| Patient Satisfaction | 3 | 2022 | 583 | 0.080 |
Why?
| Forced Expiratory Volume | 3 | 2013 | 476 | 0.080 |
Why?
| Comorbidity | 1 | 2014 | 1458 | 0.080 |
Why?
| Continuity of Patient Care | 1 | 2011 | 254 | 0.080 |
Why?
| Infant | 3 | 2021 | 7937 | 0.080 |
Why?
| Interdisciplinary Communication | 1 | 2010 | 185 | 0.080 |
Why?
| Program Development | 1 | 2011 | 345 | 0.080 |
Why?
| Peer Group | 2 | 2013 | 203 | 0.080 |
Why?
| Cooperative Behavior | 1 | 2011 | 383 | 0.080 |
Why?
| Animals | 4 | 2018 | 31837 | 0.080 |
Why?
| Inflammation | 1 | 2019 | 2485 | 0.080 |
Why?
| Odds Ratio | 2 | 2009 | 954 | 0.080 |
Why?
| Activity Cycles | 1 | 2008 | 4 | 0.080 |
Why?
| Affect | 2 | 2014 | 246 | 0.080 |
Why?
| Incidence | 2 | 2014 | 2316 | 0.080 |
Why?
| Beclomethasone | 1 | 2008 | 25 | 0.080 |
Why?
| Smoking | 2 | 2007 | 1391 | 0.080 |
Why?
| Cohort Studies | 3 | 2013 | 4903 | 0.070 |
Why?
| Patients | 1 | 2009 | 162 | 0.070 |
Why?
| Schools | 1 | 2010 | 400 | 0.070 |
Why?
| Computers | 1 | 2007 | 60 | 0.070 |
Why?
| Polysomnography | 1 | 2008 | 139 | 0.070 |
Why?
| Self Disclosure | 1 | 2007 | 59 | 0.070 |
Why?
| Social Isolation | 1 | 2007 | 52 | 0.070 |
Why?
| Monitoring, Ambulatory | 1 | 2008 | 81 | 0.070 |
Why?
| Culture | 1 | 2008 | 122 | 0.070 |
Why?
| Practice Patterns, Physicians' | 1 | 2015 | 1177 | 0.070 |
Why?
| Double-Blind Method | 2 | 2018 | 1663 | 0.070 |
Why?
| Cocaine-Related Disorders | 1 | 2007 | 107 | 0.070 |
Why?
| Child Behavior Disorders | 1 | 2007 | 131 | 0.070 |
Why?
| Self-Assessment | 2 | 2003 | 62 | 0.070 |
Why?
| Family Practice | 1 | 2010 | 427 | 0.070 |
Why?
| Software | 1 | 2010 | 537 | 0.060 |
Why?
| Infant, Newborn | 1 | 2016 | 5035 | 0.060 |
Why?
| Attitude to Health | 1 | 2009 | 406 | 0.060 |
Why?
| Health Status | 1 | 2010 | 721 | 0.060 |
Why?
| Mobile Applications | 2 | 2019 | 140 | 0.060 |
Why?
| Neuropsychological Tests | 2 | 2007 | 913 | 0.060 |
Why?
| Monocytes | 1 | 2008 | 504 | 0.060 |
Why?
| Marijuana Abuse | 1 | 2007 | 212 | 0.060 |
Why?
| Societies, Medical | 2 | 2021 | 677 | 0.060 |
Why?
| Parent-Child Relations | 2 | 2004 | 234 | 0.060 |
Why?
| Logistic Models | 3 | 2010 | 1844 | 0.060 |
Why?
| Suicide, Attempted | 1 | 2007 | 313 | 0.060 |
Why?
| Mass Screening | 2 | 2011 | 1011 | 0.060 |
Why?
| Memory, Short-Term | 1 | 2007 | 223 | 0.060 |
Why?
| Health Care Sector | 1 | 2004 | 24 | 0.060 |
Why?
| Drug Costs | 1 | 2005 | 91 | 0.060 |
Why?
| Interleukin-6 | 1 | 2008 | 676 | 0.060 |
Why?
| Administration, Intranasal | 1 | 2004 | 75 | 0.060 |
Why?
| Poverty | 2 | 2020 | 443 | 0.060 |
Why?
| Attention | 1 | 2007 | 392 | 0.060 |
Why?
| Tacrolimus | 1 | 2004 | 134 | 0.060 |
Why?
| Disease Progression | 3 | 2019 | 2392 | 0.050 |
Why?
| Patient Care | 1 | 2004 | 103 | 0.050 |
Why?
| Sensitivity and Specificity | 3 | 2019 | 1700 | 0.050 |
Why?
| Temporal Lobe | 1 | 2003 | 79 | 0.050 |
Why?
| Drug Utilization | 2 | 2018 | 167 | 0.050 |
Why?
| Self Administration | 1 | 2003 | 123 | 0.050 |
Why?
| Drug Industry | 1 | 2004 | 104 | 0.050 |
Why?
| Safety | 1 | 2005 | 297 | 0.050 |
Why?
| Motor Activity | 1 | 2007 | 642 | 0.050 |
Why?
| Amygdala | 1 | 2004 | 170 | 0.050 |
Why?
| Regression Analysis | 2 | 2016 | 947 | 0.050 |
Why?
| Activities of Daily Living | 1 | 2005 | 350 | 0.050 |
Why?
| Diagnostic Tests, Routine | 1 | 2003 | 87 | 0.050 |
Why?
| Genetic Counseling | 1 | 2002 | 65 | 0.050 |
Why?
| Mosaicism | 1 | 2002 | 61 | 0.050 |
Why?
| Alcohol Drinking | 1 | 2007 | 655 | 0.050 |
Why?
| Smoking Prevention | 1 | 2002 | 157 | 0.050 |
Why?
| Italy | 1 | 2021 | 92 | 0.050 |
Why?
| Artificial Intelligence | 1 | 2022 | 145 | 0.050 |
Why?
| Health Care Costs | 1 | 2004 | 380 | 0.050 |
Why?
| Social Behavior | 1 | 2003 | 267 | 0.050 |
Why?
| Cost of Illness | 1 | 2003 | 254 | 0.050 |
Why?
| Prenatal Diagnosis | 1 | 2002 | 168 | 0.050 |
Why?
| Immunosuppressive Agents | 1 | 2004 | 648 | 0.040 |
Why?
| Cytokines | 1 | 2008 | 1843 | 0.040 |
Why?
| Body Mass Index | 1 | 2007 | 1961 | 0.040 |
Why?
| Case-Control Studies | 3 | 2019 | 3008 | 0.040 |
Why?
| Patient Selection | 1 | 2003 | 642 | 0.040 |
Why?
| Global Burden of Disease | 1 | 2019 | 15 | 0.040 |
Why?
| Electronics | 1 | 2020 | 66 | 0.040 |
Why?
| Hippocampus | 1 | 2004 | 696 | 0.040 |
Why?
| Developmental Disabilities | 1 | 2002 | 239 | 0.040 |
Why?
| Datasets as Topic | 1 | 2019 | 98 | 0.040 |
Why?
| Homozygote | 1 | 2018 | 188 | 0.040 |
Why?
| Safety-net Providers | 1 | 2019 | 95 | 0.040 |
Why?
| Placebos | 1 | 2018 | 198 | 0.040 |
Why?
| Morbidity | 1 | 2018 | 277 | 0.040 |
Why?
| Organizational Policy | 1 | 2016 | 68 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2011 | 718 | 0.030 |
Why?
| Cognition | 1 | 2003 | 983 | 0.030 |
Why?
| Prevalence | 1 | 2002 | 2252 | 0.030 |
Why?
| Insurance Claim Review | 1 | 2016 | 67 | 0.030 |
Why?
| Diffusion of Innovation | 1 | 2016 | 94 | 0.030 |
Why?
| Intelligence Tests | 2 | 2007 | 59 | 0.030 |
Why?
| Education | 1 | 2015 | 95 | 0.030 |
Why?
| Vital Capacity | 2 | 2009 | 257 | 0.030 |
Why?
| Phenotype | 1 | 2002 | 2817 | 0.030 |
Why?
| United Kingdom | 1 | 2014 | 227 | 0.030 |
Why?
| MP3-Player | 1 | 2013 | 3 | 0.030 |
Why?
| Philadelphia | 1 | 2013 | 46 | 0.030 |
Why?
| Lung | 2 | 2023 | 3593 | 0.030 |
Why?
| Memory | 1 | 2014 | 209 | 0.030 |
Why?
| Demography | 2 | 2004 | 262 | 0.030 |
Why?
| Formoterol Fumarate | 1 | 2012 | 7 | 0.030 |
Why?
| Psychometrics | 2 | 2007 | 608 | 0.020 |
Why?
| Interview, Psychological | 1 | 2011 | 89 | 0.020 |
Why?
| Attitude of Health Personnel | 1 | 2018 | 978 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2013 | 524 | 0.020 |
Why?
| Urban Population | 1 | 2013 | 402 | 0.020 |
Why?
| Models, Organizational | 1 | 2011 | 140 | 0.020 |
Why?
| Pregnancy | 1 | 2002 | 5527 | 0.020 |
Why?
| Reproducibility of Results | 2 | 2008 | 2770 | 0.020 |
Why?
| Models, Psychological | 1 | 2011 | 296 | 0.020 |
Why?
| Emergency Medical Services | 1 | 2015 | 587 | 0.020 |
Why?
| Body Height | 1 | 2009 | 180 | 0.020 |
Why?
| Emergencies | 1 | 2009 | 146 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2008 | 387 | 0.020 |
Why?
| False Negative Reactions | 1 | 2007 | 50 | 0.020 |
Why?
| False Positive Reactions | 1 | 2007 | 109 | 0.020 |
Why?
| Task Performance and Analysis | 1 | 2007 | 159 | 0.020 |
Why?
| Models, Statistical | 1 | 2009 | 604 | 0.020 |
Why?
| Educational Status | 1 | 2007 | 409 | 0.020 |
Why?
| Child Behavior | 1 | 2007 | 220 | 0.010 |
Why?
| Internet | 1 | 2009 | 599 | 0.010 |
Why?
| Administration, Topical | 1 | 2004 | 139 | 0.010 |
Why?
| Language Disorders | 1 | 2003 | 32 | 0.010 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2003 | 27 | 0.010 |
Why?
| Magnetic Resonance Imaging | 2 | 2004 | 3053 | 0.010 |
Why?
| Dogs | 1 | 2003 | 337 | 0.010 |
Why?
| Medical Records | 1 | 2003 | 154 | 0.010 |
Why?
| Immunoglobulin E | 1 | 2003 | 317 | 0.010 |
Why?
| Age of Onset | 1 | 2003 | 448 | 0.010 |
Why?
| Disclosure | 1 | 2002 | 101 | 0.010 |
Why?
| Outpatients | 1 | 2004 | 328 | 0.010 |
Why?
| Analysis of Variance | 1 | 2004 | 1227 | 0.010 |
Why?
| Growth | 1 | 2000 | 56 | 0.010 |
Why?
| Guidelines as Topic | 1 | 2002 | 244 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2004 | 1856 | 0.010 |
Why?
| Skin | 1 | 2004 | 659 | 0.010 |
Why?
| Multivariate Analysis | 1 | 2003 | 1440 | 0.010 |
Why?
| Cross-Sectional Studies | 1 | 2007 | 4407 | 0.010 |
Why?
|
|
Bender's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|